Post hoc analysis of a phase 3 trial and extension in children aged 6–11 with severe AD: below the 40th height percentile, 31.3% on dupilumab vs 15.5% on placebo gained ≥5 height percentiles at week 16 (P<.05), 50.7% by week 52. BALP rose but stayed normal.
Secondary analysis
Irvine et al. Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study